Entering text into the input field will update the search result below

European advisory committee backs conditional approval of Shire's Natpar for hypoparathyroidism; shares off 1% premarket

Feb. 24, 2017 8:19 AM ETShire PLC (SHPG) StockBy: Douglas W. House, SA News Editor
  • The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion recommending conditional approval of Shire plc's (NASDAQ:SHPG) Natpar (rhPTH[1-84]), a recombinant human protein with the full-length 84-amino acid sequence of endogenous parathyroid hormone (PTH), for the adjunctive treatment of adults with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
  • Hypoparathyroidism, an Orphan Disease in the EU, occurs when inadequate levels of PTH are secreted by the parathyroid glands. It is characterized by low blood calcium (hypocalcemia) and high blood phosphate (hyperphosphatemia).
  • Natpar is marketed in the U.S. as Natpara.
  • Shares are off 1% premarket on light volume.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
SHPG--
Shire PLC